93 results
Page 4 of 5
8-K
EX-99.1
xk1hsvm vxllzcwow
8 Nov 19
CORRECTION – Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
2:33pm
8-K
EX-99.1
jcyiy5 umm0rfe1xc3x
7 Nov 19
Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
EX-99.1
7tvmebv9yid1b
3 Oct 19
Other Events
7:15am
8-K
EX-99.2
i7i57fi
27 Sep 19
Other Events
10:15am
8-K
EX-99.1
n3tj500 8igl6eoooq
27 Sep 19
Other Events
10:15am
8-K
EX-99.1
nxnlqo5dq6j fup0
12 Aug 19
Other Events
7:05am
8-K
EX-99.1
88i y871uy5refbbzxw
8 Aug 19
Aravive Announces Executive Management Transition Plan
5:06pm
8-K
EX-99.1
i85ee
31 Jul 19
Aravive Reports Preliminary Results ofAVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial
7:15am
8-K
EX-99.1
85enr funfo5o
8 Jul 19
Other Events
7:16am
8-K
h85pm840luw1q
31 May 19
Termination of a Material Definitive Agreement
4:16pm
8-K
EX-99.1
p2kdcyh2
8 May 19
Aravive Reports First Quarter 2019 Financial Results and Provides Recent Corporate Updates
4:15pm
8-K
EX-99.1
n7cnj8xpy7m8
5 Feb 19
Regulation FD Disclosure
7:01am
8-K
9ohhyo
13 Nov 18
Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium
7:10am
8-K
EX-99.1
dv5v5d1cpl
13 Nov 18
Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium
7:10am
8-K
EX-99.1
gbiwluqj zs3v2dc1
6 Nov 18
Aravive Reports Third Quarter 2018 Financial Results and Provides Company Updates
4:20pm
8-K
EX-99.1
wmc1pa 7zbkb
30 Oct 18
Regulation FD Disclosure
6:16am